|By Marketwired - Medical and stadtplanung Healthcare|
|Tuesday, 19 November 2013 06:00|
SOURCE: Neuronascent, Inc.
CLARKSVILLE, MD--(Marketwired - Nov 19, 2013) - Neuronascent, Inc. (www.neuronascent.com) announced today that preclinical development of Neuronascent's (the "Company") innovative Alzheimer's disease (AD) candidate, NNI-362, will move forward with IND-enabling studies through the National Institute on Aging's (NIA's) toxicology testing contract.
The NIA is part of the U.S. Government's National Institutes of Health, and its toxicology contract is part of the Institute's AD translational research program. The goal of the program is to seed early drug discovery and preclinical drug development projects in academia and in the small business community and, in doing so, increase the number of drug candidates against a variety of therapeutic targets that can be clinically developed by industry or through clinical trial programs at the NIH.
"With NIA's support, Neuronascent's therapeutic candidate moves an important step toward clinical testing as the first neuron-replacement therapy for Alzheimer's disease, a chronic neurodegenerative disorder with no effective therapies. The great promise of our technology is the restoration of neurons and new neuron growth in individuals suffering from neurodegenerative diseases," said Judith Kelleher-Andersson, Ph.D., Neuronascent's Founder, President and Chief Scientific Officer. The Company will seek industry partners for the clinical testing of its therapeutic candidates.
Safe Harbor Statement